Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (241-250 of 274) with videos related to

Pageof 28
Sort By:
Journal of Clinical Medicine|March 25, 2022
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital AdmissionKristin Larsen, Horace Spencer, Meera Mohan, et al.
Haematologica|March 16, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg, Susann M Szmania, Junaid A Khan, et al.
British Journal of Haematology|August 28, 2024
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodiesOthman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi, et al.
The Lancet. Oncology|July 22, 2014
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialFrits van Rhee, Raymond S Wong, Nikhil Munshi, et al.
Nature Communications|January 13, 2021
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myelomaEileen M Boyle, Shayu Deshpande, Ruslana Tytarenko, et al.
Blood|May 23, 2018
The presence of large focal lesions is a strong independent prognostic factor in multiple myelomaLeo Rasche, Edgardo J Angtuaco, Terri L Alpe, et al.
Experimental Hematology & Oncology|August 23, 2025
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibitionHayley M Sabol, Aric Anloague, Japneet Kaur, et al.
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2022
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple MyelomaParvathi Sudha, Aarif Ahsan, Cody Ashby, et al.
Blood|November 16, 2006
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy, Fenghuang Zhan, Bart E Burington, et al.
Pageof 28

Showing results (241-250 of 274) with videos related to

Sort By:
Pageof 28
Journal of Clinical Medicine|March 25, 2022
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital AdmissionKristin Larsen, Horace Spencer, Meera Mohan, et al.
Haematologica|March 16, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg, Susann M Szmania, Junaid A Khan, et al.
British Journal of Haematology|August 28, 2024
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodiesOthman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi, et al.
The Lancet. Oncology|July 22, 2014
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialFrits van Rhee, Raymond S Wong, Nikhil Munshi, et al.
Nature Communications|January 13, 2021
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myelomaEileen M Boyle, Shayu Deshpande, Ruslana Tytarenko, et al.
Blood|May 23, 2018
The presence of large focal lesions is a strong independent prognostic factor in multiple myelomaLeo Rasche, Edgardo J Angtuaco, Terri L Alpe, et al.
Experimental Hematology & Oncology|August 23, 2025
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibitionHayley M Sabol, Aric Anloague, Japneet Kaur, et al.
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2022
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple MyelomaParvathi Sudha, Aarif Ahsan, Cody Ashby, et al.
Blood|November 16, 2006
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy, Fenghuang Zhan, Bart E Burington, et al.
Pageof 28